IRW News: MedMira Inc.: MedMira message set active Stand by Fiscaljahr 2024 ()

IRW-PRESS: MedMira Inc.: MedMira message set active Status until Fiscaljahr 2024

Halifax, Nova Scotia, November 28, 2024 – MedMira Inc. (MedMira) (TSXV: MIR), coming soon for FY2024 Update available

Unternehmens update

I was notified of the 510(k)-Zulassung (FDA) for the Reveal® G4 HIV-1/2-Antikörper-Schnelltest in December 2023. The clinical trials have shown 100% sensitivity for HIV-1 and HIV-2. MedMiraŽs Reveal® G4 HIV-1/2-Antikörper-Schnelltest has delivered a lupenrein specification of 100% and war against HIV-2 infection and seroconversion response. The research into the HIV-2 components is done by CLIA-Labors, hospitals or hospitals, the MedMira test is used. I started following the FDA’s 510(k) testing with the US clinical trial, a CLIA test for the Reveal® G4 HIV-1/2 test that was conducted. Derzeit before the end of the final phase and the first month of the year 2025 about the state of affairs that informs and looks back on that time is an end date.

In 2024 schloss das Unternehmen seine clinical syphilis studies on a study of data at Health Canada’s In Vitro Diagnostic Division, Medical Device Directorate ein. All relevant data and fragments have been removed from that stadium. When MedMira is concentrated on the Zulassung des Reveal® TP (Syphilis) Schnelltests in Canada, how the Unternehmen zwei weitere for the Zulassung in Canada is set and all the notable information and the established control. Derzeit van de Unternehmen op de Zulassungen alle three Schnelltests und rechnet jederzeit met diesen.

In the quartet of the Geschäftsjahres 2024, the Unternehmen are two extensive Partnerships Associations for the Distribution of all kinds and zukünftige Productlines of MedMira in the United States of America. In the Anschluss an das End des Geschäftsjahres unterzeichnete MedMira two more Vertriebsvereinbarungen, die auf Ausschreibungen des Bundes and der Bundesstates in de USA abzielen, in Vorbereitung auf de Vergabezeitraum des alles Quartals des Geschäftsjahres 2025. Damit hat if part of the Präsenz und Reichweite in the Hinblick has a large volume representation for your active product (Reveal® G4 HIV-1/2 Schnelltest and Miriad®), it will be expanded and the time can be taken to apply the Reveal® G4 HIV-1/2 improve Schnelltests (CLIA-exempt product) vor.

With the start of July 2024, MedMira in Zusammenarbeit mit REACH Nexus at the MAP Center for Urban Health Solutions of St. Michael’s Hospital will receive full funding for the Canadian Institute of Health Research (CIHR) clinical studies to create Multiplo® Complete Syphilis (TP/ nTP) Anti-körper-Test (Multiplo® TP/nTP). This reaction would arise from the Ankündigung of People’s Minister Mark Holland, which would provoke a syphilis pandemic in North America.

Ausblick

The latest message from the CDC (USA), which was published in November 2024, was a clearer message about the syphilis fall in 2019 and 2023. So the CDC (USA) has a syphilis attack rate of 61% and a newborn disease rate of 106%. In Canada, the CCDR is 109% as of 2018 and 599% at birth.

MedMira has strategically positioned its product portfolio to address asymptomatic infections (infections or other symptoms) and sexual health infection status with HIV, Syphilis and Hepatitis C. This insanity is one of the most important screening and diagnostic markets after oncology. The strategic policy of the US economy is best to do what will produce the best results in the Canadian and US-American markets, which can produce the best rapid tests. When economic growth in the current time and resources is strengthened and becomes more complex, the high barrier in the market with a German lower law and an attractive return on investment is possible.

Speziell in Canada is the COVID-19 pandemic that has increased the entire Anerkennung von Schnelltests deutlich. Information about the market for MedMiras products in Canada is one of the most important products for the GJ 2025. As the world has reached a greater size of the various organizations, there has been a large flow of financial resources through MedMira, which years later comes onto the market.

Uber MedMira

MedMira is a powerful Entwickler and Hersteller of Schnelltests in vertical Fluss®. The tests of American hospitals, laboratories, hospitals and individuals make a simple diagnosis of HIV, syphilis, hepatitis and SARS-CoV-2 in three minutes. The tests of the Unternehmens were well carried out under the Marken REVEAL®, REVEALCOVID-19®, Multiplo® and Miriad® verticals. The Rapid Vertical Flow® technology patent is based on MedMira’s HIV test and is one of the only patents worldwide in Canada, the United States, China and the European Union. MedMira’s operations and manufacturing facilities are located in Halifax, Nova Scotia, Canada. For more information, please visit medmira.com and medmira.ca. Follow our Twitter and LinkedIn.

This press conference has zukunftsgerichtte Aussagen, which is concerned with risks and uncertainty and the gegenwärtige erwartungen of the Unternehmens in Bezug op zukünftige Ereignisse broaderspiegeln, einschließlich Aussagen über a possibile behördliche Zulassung, Productinführung, zukünftiges Wachstum and new Geschäftsmöglichkeiten. The results can be obtained from these enthaltene forecasts and depend on the results of factors such as these, without further explanation, with additional market conditions, follow-up and legal aspects of the clinical study, insight into the results if you Zulassungsverfahren, de Aufbau van Unternehmensallianzen und Other Risiken, die Zeit zu Zeit in de Quartalsberichten van de Unternehmens.

If the TSX Venture Exchange or the regular service of the TSX Venture Exchange (definition of the definition of the TSX Venture Exchange) follows the Verantwortung voor de Angemessenheit or de Richtingkeit Pressemitteilung.

MedMira Contact

Markus Meile

Finanzvorstand

MedMira Inc.

[email protected]

In Europe:

Swiss Resource Capital AG

Jochen Staiger

[email protected]

www.resource-capital.ch

The English original notification can be found under the following link:

https://www.irw-press.at/press_html.aspx?messageID=77634

The übersetzte Notification finds the following link:

https://www.irw-press.at/press_html.aspx?messageID=77634&tr=1

SUBSCRIBE TO NEWSLETTER:

Aktuelle Pressemeldungen die Unternehmens direkt in Ihr Postfach:

http://www.irw-press.com/alert_subscription.php?lang=de&isin=CA58501R1029

Mitteilung übermittelt by IRW-Press.com. The justifiable effect is for inhalation.

Kostenloser Abdruck mit Quellenangabe erlaubt.